Biotechnology News and Research

RSS

Genetic screening identifies genes driving resistance with guide RNA library

Researchers have developed a method to create a comprehensive library of mutations across all genes in the mouse genome. This library can be used to examine the role of every gene in different cell types.

23 Dec 2013

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced results from a 12-week, placebo-controlled Phase IIb study involving 79 patients with active rheumatoid arthritis ("RA") for its proprietary drug CF101, an A3 adenosine receptor ("A3AR") agonist.

23 Dec 2013

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

TaiGen Biotechnology Company, Limited today announced that the U.S. Food and Drug Administration has granted nemonoxacin (Taigexyn) Qualified Infectious Disease Product and Fast Track designations for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.

23 Dec 2013

Scientists discover new way to stop malaria parasites from multiplying

Scientists have taken an important step towards new malaria treatments by identifying a way to stop malaria parasites from multiplying.

22 Dec 2013

Researchers discover new way to make chemotherapy treatment effective for pancreatic cancer patients

Scientists from The University of Manchester - part of Manchester Cancer Research Centre believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients.

From The University of Manchester 21 Dec 2013

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

United Therapeutics Corporation announced today that the United States Food and Drug Administration has approved Orenitram (treprostinil) Extended-Release Tablets for the treatment of pulmonary arterial hypertension in WHO Group I patients to improve exercise capacity.

21 Dec 2013

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

BioCryst Pharmaceuticals, Inc., a pharmaceutical company focused on the development and commercialization of treatments for rare and infectious diseases, today announced that it has submitted a New Drug Application (NDA) filing for intravenous (i.v.) peramivir to the U.S. Food & Drug Administration (FDA). BioCryst is seeking an indication as the first i.v. neuraminidase inhibitor approved in the U.S. for the treatment of acute uncomplicated influenza in adults. Peramivir is approved in Japan and Korea for the treatment of influenza.

20 Dec 2013

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.

20 Dec 2013

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Baxter International Inc. today announced completion of CE marking in Europe for the VIVIA hemodialysis system, designed to deliver more frequent, extended duration, short daily or nocturnal home HD therapy, known as High Dose HD therapy.

From Baxter International Inc. 20 Dec 2013

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

A new study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) helps confirm that a molecule targeted by the experimental drug ibrutinib is critical for the development of chronic lymphocytic leukemia, the most common form of adult leukemia.

20 Dec 2013

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

Amgen today announced that the Phase 3 DESCARTES (Durable Effect of PCSK9 Antibody CompARed wiTh PlacEbo Study) study evaluating the long-term 52-week safety and efficacy of evolocumab for the treatment of high cholesterol met its primary endpoint of percent reduction from baseline in low-density lipoprotein cholesterol (LDL-C) at week 52.

20 Dec 2013

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

FibroGen, Inc., announced today that patient enrollment has started in a new Phase 2 clinical study of FG-3019 in patients who suffer from idiopathic pulmonary fibrosis.

20 Dec 2013

MicuRx announces initiation of global clinical development program for MRX-I compound

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced the initiation of a global clinical development program for its lead compound MRX-I, a novel oxazolidinone antibiotic for treatment of Gram-positive infections including methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.

20 Dec 2013

New research assesses nanomedicine-based approaches for treating cancer

As cancer maintains its standing as the second leading cause of death in the U.S., researchers have continued their quest for safer and more effective treatments. Among the most promising advances has been the rise of nanomedicine, the application of tiny materials and devices whose sizes are measured in the billionths of a meter to detect, diagnose and treat disease.

20 Dec 2013

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

Takeda Pharmaceutical Company Limited and Natrogen Therapeutics International, Inc. jointly announced today an agreement whereby Takeda will acquire an exclusive license to develop Natrogen's Natura-alpha compound as well as an option to acquire Natrogen. Natura-alpha is a synthetic small molecule oral compound that is believed to inhibit pro-inflammatory cytokine expression, which may help to reduce gastrointestinal inflammation. Natura-alpha is currently in Phase 2 development for the treatment of ulcerative colitis.

20 Dec 2013

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

Baxter International Inc. today announced that the United States Food and Drug Administration granted approval of Baxter's FEIBA [Anti-Inhibitor Coagulant Complex], the first and only FDA-approved treatment for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A or B who have developed inhibitors.

From Baxter International Inc. 20 Dec 2013

E. coli evolution studies may lead to better treatments

Going back in time to compare evolutionary changes in several thousand generations of E. coli, a University of Houston biologist hopes to one day be able to isolate a bacterial pathogen and predict the likelihood it will become resistant to a particular antibiotic.

18 Dec 2013

Researchers discover molecular "switch" in receptor that controls cell behavior

If scientists can control cellular functions such as movement and development, they can cripple cells and pathogens that are causing disease in the body.

17 Dec 2013

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Atara Biotherapeutics, Inc., a drug development company with a focus on innovative therapies for patients with debilitating diseases, announced today that it has secured $38.5 million in initial closings under its Series B financing. In this round, investors Amgen Ventures, Celgene Corporation, and EcoR1 Capital, joined existing investors Alexandria Venture Investments, DAG Ventures, Domain Associates, and Kleiner Perkins Caufield & Byers.

17 Dec 2013

Paragonix Technologies files FDA Pre-Marketing Notification Application for Sherpa Pak Transporter

Paragonix Technologies, Inc. today announced that it has successfully completed filing of a Pre-Marketing Notification Application (510(k)) with the US Food and Drug Administration for its Sherpa Pak Transporter. The Sherpa Pak Transporter is indicated for the static hypothermic preservation of kidneys during transportation and eventual transplantation into a recipient, using cold storage solutions indicated for use with the kidney.

17 Dec 2013

Biotechnology News and Research

Genetic screening identifies genes driving resistance with guide RNA library

Can-Fite reports positive results from CF101 Phase IIb study for rheumatoid arthritis

FDA grants QIDP and Fast Track designations to TaiGen's nemonoxacin

Scientists discover new way to stop malaria parasites from multiplying

Researchers discover new way to make chemotherapy treatment effective for pancreatic cancer patients

Orenitram Extended-Release Tablets get FDA approval for pulmonary arterial hypertension treatment

Biocryst seeks FDA NDA approval for Peramivir to treat influenza

Oramed reports positive results from ORMD-0801 pharmacokinetic study in type 1 diabetes patients

Baxter’s VIVIA hemodialysis system receives CE marking in Europe

Experimental drug inhibits BTK molecule in patients with chronic lymphocytic leukemia

Amgen reports that Phase 3 DESCARTES study for high cholesterol meets primary endpoint

FibroGen starts patient enrollment in FG-3019 Phase 2 study for idiopathic pulmonary fibrosis treatment

MicuRx announces initiation of global clinical development program for MRX-I compound

New research assesses nanomedicine-based approaches for treating cancer

Takeda to acquire exclusive license to develop Natrogen's Natura-alpha compound

FDA approves Baxter's FEIBA for prophylactic treatment of hemophilia patients with inhibitors

E. coli evolution studies may lead to better treatments

Researchers discover molecular "switch" in receptor that controls cell behavior

Atara Biotherapeutics secures $38.5M in initial closings under Series B financing

Paragonix Technologies files FDA Pre-Marketing Notification Application for Sherpa Pak Transporter

Event guide: 3rd IMPACCT Real World Evidence Summit Europe eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News